Yuhan Corporation's chief executive Cho Wook-je. [Photo by Lee Seung-hwan] South Korea's Yuhan Corporation is planning to construct a new factory in Eumseong, Chungbuk, as part of its global expansion strategy for Leclaza (lazertinib mesylate monohydrate), a treatment for non-small cell lung cancer. The move will help strengthen quality control (QC) and increase operating profit margins.Leclaza, a second-line treatment for non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations, received approval for an additional indication as a first-line treatment at the end of June.

https://n.news.naver.com/mnews/article/009/0005188136?sid=104

#naver